Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers

Clinical Neuropharmacology

Volumn 35, Issue 3, 2012, Pages 111-117

  Nyholm, Dag ^a   Lewander, Tommy ^a,b   Gomes Trolin, Cecilia ^b   Bäckström, Tobias ^c   Panagiotidis, Georgios ^c   Ehrnebo, Mats ^d   Nyström, Christer ^e   Aquilonius, Sten Magnus ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Life Science Management Laboratories (LSM Lab)   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d PFIZER INC   (United States)

^e Sensidose AB   (Sweden)

Author keywords

levodopa benserazide; levodopa carbidopa; microtablets; Parkinson disease; pharmacokinetics

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA;

ACUTE ABDOMEN; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG INDUCED HEADACHE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MICROTABLET; MYOCLONUS; NAUSEA; NORMAL HUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ADULT; BENSERAZIDE; CARBIDOPA; CROSS-OVER STUDIES; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEVODOPA; MALE; TABLETS; YOUNG ADULT;

EID: 84861527310     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31825645d1     Document Type: Article

References (31)

1. Lewitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008;359(23):2468Y2476.
2. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351(24):2498Y2508.
3. Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26(3):156Y163.
4. LeWitt PA, Jennings D, Lyons KE, et al. Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. Mov Disord 2009;24(9):1319Y1324.
5. Bredenberg S, Nyholm D, Aquilonius SM, et al. An automatic dose dispenser for microtabletsVa new concept for individual dosage of drugs in tablet form. Int J Pharm 2003;261(1Y2):137Y146.
6. Lucarelli C, Betto P, Ricciarello G, et al. Simultaneous measurement of L-dopa, its metabolites and carbidopa in plasma of parkinsonian patients by improved sample pretreatment and high-performance liquid chromatographic determination. J Chromatogr 1990;511:167Y176.
7. Titus DC, August TF, Yeh KC, et al. Simultaneous high-performance liquid chromatographic analysis of carbidopa, levodopa and 3-O-methyldopa in plasma and carbidopa, levodopa and dopamine in urine using electrochemical detection. J Chromatogr 1990; 534:87Y100.
8. Blandini F, Martignoni E, Pacchetti C, et al. Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl 1997;700(1Y2):278Y282.
9. ICH Topic Q 2 B, Validation of Analytical Procedures: Methodology, Note for guidance on validation of analytical procedures (CPMP/ICH/281/95).
10. Guidance for Industry, Bioanalytical Method Validation, U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation Research (CDER) and Center for Veterinary Medicine (CVM), May 2001.
11. Da Prada M, Kettler R, Zurcher G, et al. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Eur Neurol 1987;27(suppl 1):9Y20.
12. Goole J, Van Gansbeke B, Pilcer G, et al. Pharmacoscintigraphic and pharmacokinetic evaluation on healthy human volunteers of sustained-release floating minitablets containing levodopa and carbidopa. Int J Pharm 2008;364(1):54Y63.
13. Nutt JG. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 1987;22(4):535Y540.
14. Nyholm D, Karlsson E, Lundberg M, et al. Large differences in levodopa dose requirement in Parkinson's disease: men use higher doses than women. Eur J Neurol 2010;17(2):260Y266.
15. Kuoppamaki M, Korpela K, Marttila R, et al. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol 2009;65(5):443Y455.
16. Fabbrini G, Juncos J, Mouradian MM, et al. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21(4):370Y376.
17. Murata M, Mizusawa H, Yamanouchi H, et al. Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off. J Neural Transm 1996;103(10):1177Y1185.
18. Martinelli P, Contin M, Scaglione C, et al. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences? Neurol Sci 2003;24(3):192Y193.
19. Contin M, Riva R, Martinelli P, et al. Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. Eur J Clin Pharmacol 1991;41(5):463Y466.
20. Nagayama H, Ueda M, Kumagai T, et al. Influence of ageing on the pharmacokinetics of levodopa in elderly patients with Parkinson's disease. Parkinsonism Relat Disord 2011;17(3):150Y152.
21. Nyholm D, Lennernas H. Irregular gastrointestinal drug absorption in Parkinson's disease. Expert Opin Drug Metab Toxicol 2008;4(2):193Y203.
22. Bayer AJ, Day JJ, Finucane P, et al. Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia. J Clin Pharm Ther 1988; 13(3):191Y194.
23. Contin M, Riva R, Martinelli P, et al. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease. Clin Neuropharmacol 1999;22(6):351Y355.
24. Merims D, Djaldetti R, Melamed E. Waiting for ON: a major problem in patients with Parkinson disease and ON/OFF motor fluctuations. Clin Neuropharmacol 2003;26(4):196Y198.
25. Pahwa R, Lyons KE. Levodopa-related wearing-off in Parkinson's disease: identification and management. Curr Med Res Opin 2009;25(4):841Y849.
26. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006; 13(11):1186Y1202.
27. Fahn S. How do you treat motor complications in Parkinson's disease: medicine, surgery, or both? Ann Neurol 2008;64(suppl 2):S56YS64.
28. Nyholm D. The rationale for continuous dopaminergic stimulation in adVanced Parkinson's disease. Parkinsonism Relat Disord 2007;13 (suppl 13):S13YS17.
29. Nyholm D, Askmark H, Aquilonius SM. Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint. Ann Neurol 2011;69(2):424.
30. Pappert EJ, Goetz CG, Niederman F, et al. Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology 1996;47(6):1493Y1495.
31. Kurth MC. Using liquid levodopa in the treatment of Parkinson's disease. A practical guide. Drugs Aging 1997;10(5):332Y340.